Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.

@article{Tsouana2015DeferasiroxFI,
  title={Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.},
  author={Eva Tsouana and Banu Kaya and Nimze Gadong and Claire J Hemmaway and Heather Newell and Andrea Simmons and Simon Whitmarsh and Paul T. Telfer},
  journal={European journal of haematology},
  year={2015},
  volume={94 4},
  pages={336-42}
}
Deferasirox (DFX) has been licensed for iron chelation in patients with sickle cell disease (SCD), but there is limited data on its long-term efficacy and safety in children. This retrospective study included 62 regularly transfused children managed in the East London and Essex Clinical Haemoglobinopathy Network (mean age 9.2 ± 3.2 yr). Efficacy measurements consisted of monthly serum ferritin (SF) and annual R2 MRI-estimated liver iron concentration (LIC), and safety markers included serum… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS